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Abstract
Objectives—The primary objective of this multicenter registry was to study the prognostic value
of PET MPI and the improved classification of risk in a large cohort of patients with suspected or
known coronary artery disease (CAD).
Background—Limited prognostic data are available for myocardial perfusion imaging (MPI)
with positron emission tomography (PET).
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Methods—7,061 patients from 4 centers underwent a clinically indicated rest/stress rubidium-82
PET MPI with a median follow-up of 2.2 years. The primary outcome of this study was cardiac-
death (169 patients) and the secondary outcome was all-cause death (570 patients). Net
reclassification improvement (NRI) and integrated discrimination (IDI) analyses were performed.
Results—Risk-adjusted hazard of cardiac-death increased with each 10% abnormal myocardium
with mildly, moderately or severely abnormal stress PET [hazard ratio 2.3 (95% CI 1.4–3.8,
P=0.001), 4.2 (95% CI 2.3–7.5, P<0.001), and 4.9 (95% CI 2.5–9.6, P <0.0001), respectively,
normal MPI: referent]. Addition of %myocardium ischemic and scarred to clinical information
(age, female sex, body mass index, history of hypertension, diabetes, dyslipidemia, smoking,
angina, betablocker use, prior revascularization and rest heart rate) improved the model
performance [C-statistic 0.805 (95% CI, 0.772–0.838) to 0.839 (95% CI, 0.809–0.869)] and risk
reclassification for cardiac-death [NRI 0.116 (95% CI 0.021–0.210)] with smaller improvements
in risk assessment for all-cause death.
Conclusions—In patients with known or suspected CAD, the extent and severity of ischemia
and scar on PET MPI provide powerful and incremental risk estimates of cardiac-death and all-
cause death compared to traditional coronary risk factors.
Keywords
positron emission tomography; registry; prognosis; myocardial perfusion imaging; risk
reclassification
INTRODUCTION
Several studies have demonstrated the prognostic value of positron emission tomography
(PET) myocardial perfusion imaging (MPI)(1–7) using conventional metrics (significant
hazard ratio in multivariable risk adjusted models, increment in model Chi square value,
improved model fit by a lower Akaike information criterion (AIC), and an increase in the
area under the receiver operator characteristic curve). While these conventional metrics have
demonstrated a strong and independent association between abnormal MPI and adverse
clinical outcomes, these were relatively small and single-center studies and were limited in
determining the clinical utility of the PET MPI. The clinical utility of a risk marker is its
ability to reclassify risk when added to the traditional risk model. Improved risk
reclassification will allow us to make clinical decisions that may lead to changes in
management and clinical outcomes. Therefore, the aim of our study was to determine the
incremental prognostic value and the clinical utility of rest and stress perfusion defects on
PET MPI over clinical risk factors using the traditional and novel metrics of risk
reclassification in a large number of patients with known or suspected CAD using a large
multi-center PET registry.
METHODS
Registry methods
Four centers participated in this multi-center PET registry and enrolled 7,061 patients. Each
center enrolled a patients clinically referred for a pharmacological stress Rubidium-82
(Rb-82) MPI. Data from some of the patients (n=3,884) were included in prior publications.
(2,4,6,8,9) Each center had institutional review board approval for the study. Study methods
are shown in much greater detail in the Appendix section.
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Myocardial perfusion imaging methods
Patients were instructed to refrain from caffeine intake for at least 12 hours prior to the
vasodilator study. Each patient underwent Rb-82 MPI using a dedicated or a hybrid PET/CT
scanner using site specific protocols.
Follow-up methods
Cardiac-death was the primary end-point and all-cause death the secondary endpoint of this
study. During follow-up, 3 of the 4 centers ascertained the cause of death and identified 169
cardiac-deaths in 6, 037 patients (2.9%, 2.9% and 2.2%, at each site). This cohort was used
for the analyses of the primary end-point, cardiac-death. All-cause death (N=570) was
studied in 7, 061 patients from 4 sites (9.8%, 8.2%, 9.2% and 3.9%, at each site). The
median duration of follow-up for the entire cohort was 2.2 years (interquartile range, 1.3–3.3
years).
Statistical Analysis
We employed standardized approaches to data analysis including comparisons of categorical
variables with χ2 statistics and t-tests for continuous measures.
Survival Analyses and Prognostic Value
Univariable associations of clinical and PET variables with death outcomes were evaluated
using Cox proportional hazards models. Kaplan-Meier survival curves were plotted.
In our multivariable Cox model, we examined the unique increase in the relative hazard for
cardiac-death and all-cause death by % scarred and % ischemic perfusion abnormalities on
MPI. All variables for the Cox models were chosen a priori and included age, coronary risk
factors, medication use and symptoms on presentation along with the PET data.
Analyses for incremental prognostic value and risk reclassification
Predicted cardiac-death from each Cox model was subset into 3 categories using the
previously established risk thresholds of < 1%, 1–2.9% and > 3%/year (events rates at 2
years of follow-up are shown in the results).(10) Predicted all-cause death was subset into 3
categories including < 2.5%, 2.5–7.4%, and ≥ 7.5% /year (events rates at 2 years of follow-
up are shown in the results). Higher risk thresholds were used for all-cause death based on
the distribution of cardiac-deaths and all-cause deaths in the 6, 037 patients with both events
recorded. The NRI methodologies of Pencina were applied including both categorical and
continuous estimates,(11) using SAS methods for calculating the NRI for survival data.
(11,12) In 2,102 patients with rest left ventricular ejection fraction (LVEF) data, we
explored the incremental prognostic value of PET MPI to a clinical model incorporating rest
LVEF.
RESULTS
The baseline demographics and risk factors stratified by categories of % myocardium
abnormal at stress are listed in Table 1. The percent of normal scans in this registry was 44%
(47%, 40%, 57%, and 41%, respectively for each of the sites in this registry).
Univariable associations between cardiovascular risk factors, Rb-82 PET MPI and
outcomes
The univariable clinical and PET predictors of cardiac-death and all-cause death are listed in
Table 2 and online Table 1. The % myocardium abnormal, % myocardium ischemic, and %
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myocardium scarred were significant univariable predictors of cardiac-death and all-cause
death (Figures 1A and 1B).
Multivariable Cox Models for the estimation of cardiac-death
The independent predictors of cardiac-death (N=6, 037, Table 3,) and all-cause death (N=7,
061, appendix Table 2) were determined using separate multivariable Cox-proportional
hazards models. The % myocardium ischemic and % myocardium scarred were independent
predictors of cardiac-death and all-cause death. For each 10% increase in % myocardium
ischemic and % myocardium scarred, the hazard of cardiac-death increased by 34%, and
57% respectively. After adjustment for the listed covariates, compared to patients with
normal stress PET MPI, the relative hazard of cardiac-death was 2.3 (95% CI=1.4–3.8,
p=0.001), 4.2 (95% CI=2.3–7.5, p<0.001) and 4.9 (95% CI=2.5–9.6, p<0.0001),
respectively, for patients with 0.1–9.9%, 10–19.9%, and ≥20% of the myocardium abnormal
at stress (Figure 2A).
In 2, 101 patients with rest LVEF, Cox models including the clinical variables with rest
LVEF and then adding the PET variables (% myocardium ischemic and % myocardium
scarred), showed that a 10% points higher rest EF was associated with a lower hazard of
cardiac-death (HR 0.57, 95% CI: 0.46–0.70, P<0.0001). After accounting for the clinical
variables and rest LVEF, for each 10 % myocardium ischemic there was an 84% higher
hazard of cardiac-death (HR 1.84, 95% CI: 1.40–2.41, P <0.0001), while for each 10% and
myocardium scarred there a trend toward a 23% higher hazard of cardiac-death (HR 1.23,
95% CI: 0.96–1.56, P =0.09). The addition of % myocardium ischemic and scarred to the
clinical model including LVEF resulted in an increment in model Chi square value from 110
to 127, P <0.0001 and an increment in model C statistic from 0.844 to 0.875 (P=0.05).
Multivariable Cox Models for the estimation of all-cause death
The % myocardium ischemic and % myocardium scarred were independent predictors of
all-cause death (Appendix Table 2).
Incremental prognostic value of PET MPI using conventional and novel risk
reclassification metrics
Tables 3 and 4, show the incremental value of PET MPI over clinical risk factors using
conventional parameters of model fit: chi square value, model AIC value; model global
performance: change in C-statistic, IDI and continuous NRI and model clinical value: NRI
with categories. For cardiac-death, the addition of the % myocardium ischemic and scarred
significantly improved the model fit as well as the global performance of the model. In
contrast, the results for all-cause death (Appendix Table 2) also showed improved model fit
and global performance, but, of a much smaller magnitude compared to cardiac-death.
In order to estimate the incremental clinical prognostic value, we determined the net
reclassification of risk after the addition of the PET MPI information (% myocardium
ischemic and % myocardium scarred) to the baseline clinical information. As shown in the
Table 4 (cardiac-death, N=6, 037), the majority of patients remained at the same risk level
(diagonal values from left upper to the right lower cells), for the events and non-events.
Reclassification of cardiac-death
The addition of the % myocardium ischemic and % myocardium scarred to a baseline model
with clinical factors resulted in significant clinical incremental value for prediction of
cardiac-death. The model IDI was 0.018 (95% CI 0.01–0.03), with a relative IDI of 33.6 %
(95% CI 14.3%–55.9%). The continuous NRI was 54.0 % (95% CI 37.9%–71.4%), for
annual risk categories of < 1 %, 1.0–2.9% and ≥ 3.0%, NRI was 11.6 % (95% CI, 2.1% –
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21%) (Table 4). The addition of % myocardium ischemic and % myocardium scarred to the
clinical model more correctly reclassified cardiac-death in about 12% of patients. The
majority of the reclassification was observed in the intermediate clinical risk group.
In patients with rest LVEF data, the addition of the % myocardium ischemic and %
myocardium scarred to a baseline model with clinical factors and rest LVEF, resulted in
significant clinical incremental value for prediction of cardiac-death. The IDI was 0.017
(0.002–0.037), and the relative IDI was 0.226 (0.029–0.467). The continuous NRI was 0.504
(95% CI 0.205–0.794) and for annual risk categories of < 1 %, 1.0–2.9% and ≥ 3.0%, NRI
was 0.075 (95% CI, 0.008–0.149). The % myocardium ischemic and scarred provided
incremental value to the clinical model which included rest LVEF and more correctly
reclassified cardiac-death in 8% of patients.
For all-cause death, the NRI results also showed added value of risk classification with PET
MPI, although the magnitude of reclassification was lower than for cardiac-death (Appendix
Table 2).
DISCUSSION
The current report is the first multicenter registry to examine prognosis in 7, 061 subjects
undergoing pharmacological stress Rb-82 PET MPI. In the largest study to date, our results
demonstrate that for the prediction of cardiac-death and all-cause death, an abnormal PET
MPI provides significant incremental prognostic value over the clinical factors. Patients with
a severely abnormal stress PET MPI had almost a 5-fold higher hazard of cardiac-death
compared to patients with a normal PET MPI, even after accounting for clinical risk
markers. Also, an abnormal PET MPI along with clinical risk markers provided significant
risk reclassification in 12% of patients, confirming the clinical utility of PET MPI. This
study provides the initial strong evidence that the magnitude of scar and ischemia on PET
MPI can be a powerful tool for risk reclassification of subjects with known or suspected
CAD. Importantly, this multicenter registry provided an enriched cohort of patients with
geographic diversity imaged on a variety of imaging devices making the results much more
generalizable than prior single center studies.
Risk reclassification is a relatively novel concept that has been applied to the assessment of
other risk markers such as calcium score(13), c-reactive protein(14 ) and more recently
reported with SPECT MPI (15) and coronary flow reserve by quantitative PET MPI.
(8,16,17) To our knowledge this is likely the first study assessing risk reclassification with
rest and stress perfusion defects on PET MPI compared to clinical factors. By demonstrating
significant risk reclassification for every 10% ischemic myocardium, this study confirms a
threshold of >10% ischemic myocardium as significant for risk stratification with PET MPI,
similar to that previously established with SPECT MPI.(18) The results of this study provide
evidence that the magnitude of ischemia and scar on PET MPI provide for a significant
improvement (large effect size based on a continuous NRI 0.540) (12) in clinical risk
stratification; risk is reclassified more appropriately in 11.6 % of the patients for cardiac-
death, potentially aiding in management decisions. Further, in exploratory analyses, it
appears that the knowledge of magnitude of ischemia on PET MPI results in reclassification
of 7.5% of patients compared to the clinical variables including rest LVEF. The NRI can
provide an excellent measure for assessing the clinical utility of a novel risk marker.(11,15)
The NRI value of a novel risk marker can be compared to that of another marker within the
same patient cohort. However, direct comparison of the NRI values between different study
cohorts may be challenging due to the inherent differences in the patient risk characteristics
and the clinical variables used in the respective studies. Hence, whether the clinical utility of
rest or stress perfusion defects by PET MPI is superior to or similar to that published with
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SPECT MPI on the basis of NRI cannot be definitively determined. Also, it is important to
recognize that although reclassification of risk suggests that management and outcomes
would be potentially altered based on the results of the PET MPI study, larger prospective
clinical trials would be necessary to demonstrate changes in clinical management and
outcome.
While several single center studies have shown that relative PET, quantitative PET MPI, and
PET assessed coronary flow reserve(8,16,17) provide risk stratification for cardiovascular
outcomes, data about improved risk reclassification with PET MPI are limited.(8,16) The
current study demonstrates that relative PET MPI provides for improved risk reclassification
of 12% of patients, over clinical variables, while, recent studies showed that coronary flow
reserve assessed by quantitative PET MPI provides additional risk reclassification of
between 10%–11% of patients.(8,16) Also, the addition of measures of atherosclerosis such
as calcium score (19) or CT coronary angiography (20) may also provide additional risk
stratification to relative PET MPI. However, it remains to be seen whether measures of
coronary atherosclerosis provide incremental reclassification of risk compared to relative
PET MPI.
PET MPI offers several clinical advantages compared to SPECT MPI(21); image quality is
superior, test specificity for the diagnosis of obstructive CAD higher and identification of
scar and ischemia is better with PET MPI. As shown recently, ischemia and scar can
modulate the prognostic value of MPI (22). PET MPI is particularly advantageous in high
clinical risk cohorts such as those undergoing pharmacological stress testing, and patients
with heart failure or obesity.(21) Importantly, the incremental clinical value of PET MPI is
attained at a significantly lower estimated effective radiation dose to the subjects (~2.0 to
3.7 mSv (23,24) with Rb-82 MPI compared to ~10–12 mSv with Technetium-99m
MPI(25)), and at a much faster pace compared to SPECT MPI. However, when compared to
SPECT, the evidence supporting the clinical utility of PET MPI is limited. Although the
prognostic value of SPECT MPI has been described in several tens of thousands of patients,
the prognostic value of PET MPI is only available in several thousands of patients. The
results of the current study are critical to advance the field and guide more effective use of
PET MPI in clinical practice.
Likewise, the prognostic value of CT coronary angiography is being currently established.
However, while CT coronary angiography provides information about the nature and
anatomic extent and severity of coronary atherosclerosis, SPECT and PET MPI provide
information about myocardial blood flow; PET MPI takes into account underlying CAD,
collateral flow, myocardial adaptation to wall stress and other factors, and can also be used
in patients with renal insufficiency.
Study Strengths and Limitations
This is a large multicenter registry comprised of patients from 4 medical centers with the
attended strengths, limitations and biases. Cardiac-death was analyzed only in 6,037
patients. Renal failure was not included in this analysis, reproducibility of scan
interpretation between the medical centers was not measured, the prognostic value of PET in
patients without angina or dyspnea was not specifically studied. Also, LVEF was not
available in all the subjects and inclusion of LVEF may potentially alter the relation between
scarred myocardium and outcomes. Data on early revascularization was not available from
all the centers, so we were not able to test whether patients with abnormal imaging findings
would be more likely to benefit from revascularization. However, the inclusion of patients
with early revascularization may serve to strengthen our results, since revascularization
would be expected to attenuate the relation between PET MPI and clinical outcomes. Lastly,
majority of the perfusion studies were scored visually, but one site used automated software
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analysis. Automated quantitation of MPI is well validated for risk assessment and
comparable to visual analyses.(26) Yet, the multisite registry design overcomes the
limitations inherent to data from single centers in terms of homogeneity of patient
population and data spanning a decade of imaging, further expanding the diversity and
generalizability of the study results. The large study cohort allowed us adequate power to
study measures of risk reclassification, which would not be possible by data from any of the
individual centers.
CONCLUSIONS
Despite widespread clinical use of PET MPI for its superior diagnostic accuracy and safety
profile, the evidence for incremental risk stratification with PET MPI is limited. The results
of this large multicenter registry demonstrate that in patients with known or suspected CAD,
Rb-82 PET MPI provides powerful and incremental risk stratification. Assessment of the
magnitude of ischemia and scar on PET MPI adds to the reclassification of risk for cardiac-
death in 1 in 9 patients undergoing clinical PET MPI.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Unadjusted Hazard of Events by % Abnormal Myocardium on Vasodilator Stress
Rb-82 PET
Hazard of cardiac-death (A, 6, 037 patients, N= 169 cardiac-deaths) and all-cause death (B,
7,061 patients, N=570 all-cause deaths) was lowest in patients with normal PET MPI and
increased gradually in patients with minimal, mild, moderate or severe degrees of scan
abnormality.
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Figure 2. Risk-Adjusted Hazard of Events by % Abnormal Myocardium on Vasodilator Stress
Rb-82 PET
Hazard of cardiac-death (A, 6, 037 patients, N= 169 cardiac-deaths)and all-cause death (B,
7,061 patients, N=570 all-cause deaths) was lowest in patients with normal PET MPI and
increased gradually in patients with minimal, mild, moderate or severe degrees of scan
abnormality.
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Table 2
Univariable Hazard Ratios for Cardiac-death (N=6, 037)
Variables HR 95.0% CI for HR P-Value
Age* 1.80 1.70–1.90 <0.0001
Female sex 0.50 0.92–1.80 <0.0001
Hx Hypertension 1.29 1.19–1.50 <0.0001
Hx Diabetes 2.41 1.77–3.28 <0.0001
Hx Dyslipidemia 0.81 0.59–1.10 <0.0001
Hx Smoking 1.24 0.88–1.75 0.2
Hx Angina 0.66 0.48–0.89 0.007
Body mass index 0.97 0.95–0.99 0.006
Hx PCI 1.57 1.10–2.30 0.02
Hx CABG 2.36 1.66–3.36 <0.0001
Aspirin 1.20 0.86–1.70 0.3
Beta-blockers 1.45 1.06–1.97 <0.0001
Rest heart rate* 1.30 1.30–1.40 <0.0001
% Myo abnormal* 1.60 1.60–180 <0.0001
% Myo scarred* 1.90 1.70–2.10 <0.0001
% Myo ischemic* 1.70 1.50–1.90 <0.0001
HR = hazard ratio ; CI = confidence interval; Hx = history of; PCI = percutaneous coronary intervention; CABG = coronary artery bypass surgery;
myo = myocardium;
*per 10 unit change.
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Table 4
Risk Reclassification for Risk in 6, 037 Subjects With and Without Cardiac-death
Subjects with cardiac-death
PET model Overall
Clinical model Risk Categories
Risk Categories <1.0% 1.0% – 2.9% ≥ 3.0%
<1.0% 70.4 (88.9%) 8.8 (11.1%) 0 (0%) 79.2
1.0% – 2.9% 12.0 (17.7%) 34.8 (51.4%) 20.9 (30.9%) 67.7
≥ 3.0% 0 (0%) 7.3 (42.6%) 9.9 (57.4%) 17.2
Overall 82.4 50.9 30.8 164.1
Subjects without cardiac-death
<1.0% 3503.6 (96.2%) 122.2 (3.4%) 15 (0.4%) 3640.8
1.0% – < 2.9% 364 (23.1%) 1075.2 (68.3%) 135.1 (8.6%) 1574.3
≥ 3.0% 0 (0%) 206.7 (31.4%) 451.2 (68.6%) 657.8
Overall 3867.6 1404.1 601.2 5872.9
NRI = Net reclassification improvement. NRI continuous = 0.540 (95% CI 0.379–0.714); NRI categories = 0.116 (95% CI 0.021–0.210). Table
depicts predicted events rates at 2 years.
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